Translumina GmbH

The vascular stents market is anticipated to grow due to the growing prevalence of various vascular diseases such as carotid artery diseases, atherosclerosis, and others. In addition, rising preferences for minimally invasive surgeries are also expected to bolster the vascular stents market in the forthcoming years. LAS VEGAS, June 29, 2022 /PRNewswire/ -- DelveInsight's Vascular Stents Market Insights report provides the current and forecast market, forthcoming device innovation, individual leading companies' market shares, challenges, vascular stents market drivers, barriers, and trends, and key vascular stents companies in the market. Key Takeaways from the Vascular Stents Market As per DelveInsight estimates, North America is anticipated to dominate the global vascular stents market during the forecast period. The leading vascular stents companies include Medtronic, Abbott, Boston Scientific Corporation, BIOTRONIK SE & Co. KG, B. Braun Melsungen AG, Terumo Corporation, eucatech AG, MicroPort Scientific Corporation., Meril Life Sciences Pvt. Ltd., Vascular Concepts (SMT), W. L. Gore & Associates, Inc., Becton, Dickinson and Company., ENDOLOGIX LLC., Biosensors International Group, Ltd., Lombard Medical, Translumina GmbH, JOTEC GmbH, iVascular, Cordis, Cook, SCITECH, and several others are currently working in the vascular stents market. In May 2022, Medtronic received the FDA approval for the latest generation drug-eluting coronary stent system, Onyx Frontier™ In June 2021, Abbott received FDA clearance for its XIENCE drug-eluting family of stents for one-month (as short as 28 days) DAPT labeling for high bleeding risk (HBR) patients in the US. Thus, owing to such developments in the market, rapid growth will be observed in the vascular stents market during the forecast period. To read more about the latest highlights related to vascular stents, get a snapshot of the key highlights entailed in the Vascular Stents Market Report Vascular Stents Vascular stents are small tubular scaffolds generally used in the treatment of arterial stenosis to prevent acute vessel closure and late restenosis in a variety of vessels such as coronary arteries. The procedure in which these stents are used is known as vascular stenting. These stents are indicated to widen arteries clogged with deposits. There are various types of vascular stents available. The simplest and conventional stents are bare metal stents arranged into an expandable mesh, whereas there are advanced vascular stents that slowly elute drugs and some with the capability of slowly dissolving in the strengthening of blood vessels. Vascular Stents Market Insights Geographically, the global vascular stents market is studied in North America, Europe, Asia-Pacific, and the Rest of the World. In terms of revenue share, North America currently leads the global market and is projected to hold its vascular stents market position during the study period. This is owing to the rising obesity levels, rising hypertension among the population, an increase in alcohol consumption, and smoking, which often lead to various cardiovascular disorders such as coronary heart and peripheral vascular disorders, which require vascular stenting as a treatment. In addition, the presence of key market players and their strategic business activities such as collaboration, approval, and launch of the product, among others, are likely to bolster the regional vascular stents market in the upcoming years. To know more about why North America is leading the market growth in the vascular stents market, get a snapshot of the Vascular Stents Market Analysis Vascular Stents Market Dynamics The global vascular stents market is expected to grow at a significant rate owing to an increase in the number of angioplasties performed across the globe. Furthermore, the escalating burden of the geriatric population, the rise in technological advancements in the vascular stents product arena, and a steep rise in product approval & launches, among others, are some of the factors responsible for contributing to the growth of the vascular stents market. Moreover, increased patient preferences for minimally invasive surgeries are expected to drive up demand for vascular stents. This is due to the fact that, as compared to bypass surgery, balloon angioplasty and vascular stent implantation are far less invasive, low-risk, and low-cost procedures. However, the risk associated with vascular stents and the product's onerous regulatory approval procedure are anticipated to hamper the growth of the vascular stents market. Moreover, the unprecedented COVID-19 outbreak slowed the global vascular stents market during the initial phases. Nationwide lockdown, canceled or denied elective surgeries to prevent the transmission of the infection, and disruptive supply chain due to logistical restrictions across the border are some of the reasons that lead to the sluggish growth of the vascular stents market. Get a sneak peek at the vascular stents market dynamics @ Vascular Stents Market Dynamics Analysis Scope of the Vascular Stents Market Report Coverage : Global Study Period: 2019–2027 Market Segmentation By Product Type: Coronary Stents, Peripheral Stents (Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other), Evar Stent Grafts (Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents) Market Segmentation By Type: Bare-Metal Stents, Drug-Eluting Stents Market Segmentation By Material: Metal And Polymer Market Segmentation By Mode of Delivery: Balloon-Expandable Stents and Self Expandable Stents Market Segmentation By End-User: Hospitals and Ambulatory Surgical Centers Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Key Vascular Stents Companies: Medtronic, Abbott, Boston Scientific Corporation, BIOTRONIK SE & Co. KG, B. Braun Melsungen AG, Terumo Corporation, eucatech AG, MicroPort Scientific Corporation., Meril Life Sciences Pvt. Ltd., Vascular Concepts (SMT), W. L. Gore & Associates, Inc., Becton, Dickinson and Company., ENDOLOGIX LLC., Biosensors International Group, Ltd., Lombard Medical, Translumina GmbH, JOTEC GmbH, iVascular, Cordis, Cook, SCITECH, among others Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View DelveInsight Analysis: The vascular stents market size is expected to grow at a CAGR of 7.90% to reach about USD 21.01 billion by 2027. Which MedTech key players in the vascular stents market are set to emerge as the trendsetter explore @ Vascular Stents Companies Table of Contents Interested in knowing how the vascular stents market will be growing by 2027? Click to get a snapshot of the Vascular Stents Market Analysis Related Reports Vascular Grafts Pipeline Vascular Grafts Pipeline Insight and Competitive Landscape, 2022 report provides comprehensive insights about the pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, along with the vascular grafts companies, including RegenaGraft, Humacyte Inc, Innovia LLC, LeMaitre Vascular Inc, among others. Vascular Access Devices Market Vascular Access Devices Market Insight, Competitive Landscape, and Market Forecast, 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key vascular access devices companies, including Cook Medical Inc., Becton, Dickinson, and Company, Teleflex Incorporated, among others. Coronary Stents Market Coronary Stents Market Insight, Competitive Landscape, and Market Forecast, 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key coronary stents companies, including Medtronic, Abbott, Boston Scientific Corporation, Biosensors International Group, Ltd., BIOTRONIK SE & Co. KG, among others. Drug-Eluting Stents Market Drug-Eluting Stents Market Insight, Competitive Landscape, and Market Forecast, 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key drug-eluting stents companies including Abbott, Medtronic, Boston Scientific Corporation, B. Braun Melsungen AG, among others. Atherosclerosis Pipeline Atherosclerosis Pipeline Insight, 2022 report provides comprehensive insights into the pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, along with the atherosclerosis companies including Regeneron, Sanofi, Immunitor, Novartis, MedImmune, among others. Atherectomy Devices Market Atherectomy Devices Market Insight, Competitive Landscape, and Market Forecast, 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key atherectomy devices companies including Koninklijke Philips N.V., Medtronic, Boston Scientific Corporation, among others. Other Trending Reports Pars Plantis Market | Liver Angiosarcoma Market | Degenerative Disc Disease Market | Negative Pressure Wound Therapy Systems Market | Paraganglioma Market | Venous Stenosis Market | Tenosynovitis Market | Systemic Mastocytosis Market | Supraventricular Tachycardia Market | Small Cell Lung Cancer Market | Severe Acute Respiratory Syndrome Coronavirus Infection Market | Secondary Hyperparathyroidism Market | Retinal Vein Occlusion Market | Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market | Preeclampsia Market Related Healthcare Blogs Upcoming Cardiovascular Disease Drugs Heart Failure Market Abdominal Aortic Aneurysm Treatment Landscape About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

ROCKAWAY, NJ, Aug. 24, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced a reseller agreement with Red One Medical Devices, LLC. (Red One). The partnership will further expand availability of electroCore’s gammaCore platform in the federal marketplace. Red One is a Service-Disabled Veteran-Owned Small Business (SDVOSB) offering medical and pharmaceutical goods and services to the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) hospitals, ensuring compliance with contracting regulations, and providing logistical solutions connected directly into government contracting portals such as ECAT, GSA, DAPA, BPA, and DIBBS.“As a VA and DoD private sector partner for medical innovation, we are excited to partner with electroCore,” said Charles Pollak, President of Red One. “Their gammaCore therapy may help thousands of military personnel, family and veterans suffering from primary headache. Painful and disabling headaches torment more than 20% of former service members, especially those from the post-9/11 combat veteran cohort. We look forward to partnering with electroCore to make the therapy more easily accessible in the federal marketplace.”“Partnering with Red One will help accelerate adoption of electroCore’s therapy within the government channel,” commented Dan Goldberger, Chief Executive Officer of electroCore. “Our partnership gives electroCore access to a variety of contracting portals enabling easier procurement of gammaCore therapy across veteran and active military channels. We have just begun to scratch the surface of the help we can provide to our veterans, troops, and family members in VA and DoD, and we are honored to partner with an SDVOSB to make gammaCore more widely available to those veterans and active-duty military who can benefit from our therapy.” About Red One Medical Devices, LLCRed One is transforming healthcare for America’s military service members and veterans. Red One identifies and delivers advanced medical and pharmaceutical technologies to the federal government. These products meet the unique needs of military surgeons and patients. They are clinically proven to improve treatment outcomes in both the DoD and VA. Red One accelerates the procurement process, oftentimes making products available to the government before they’re offered in the private sector. Their team is on a mission to provide veterans with top quality care. With over 90 combined years of experience in medical sales and government contracting, Red One provides medical and pharmaceutical companies access to the federal marketplace. Red One is a government certified Service-Disabled Veteran Owned Small Business (SDVOSB) and Disability-Owned Business Enterprise (DOBE). Red One connects leading medical and pharmaceutical manufacturers to US Department of Veterans Affairs (VA) and Department of Defense (DoD) hospitals. About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache and migraine and the acute treatment of migraine and episodic cluster headache.For more information, visit . About gammaCoreTMgammaCoreTM (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients. gammaCore (nVNS) is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults. gammaCore is contraindicated for patients if they: Safety and efficacy of gammaCore have not been evaluated in the following patients: Please refer to the gammaCore Instructions for Use for all of the important warnings and precautions before using or prescribing this product. Forward-Looking StatementsThis press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's anticipated benefits of accessing Red One’s federal marketplace network; its business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the availability and impact of payer coverage, the potential of nVNS generally and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at .